Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4092-4101 | ISSN:2251-6731

Minimally Invasive Approaches in Abdominal Surgery: Outcomes, Complications and Patient Quality of Life.

Viktoria Shkabrova[1], Asiya Enikeeva[1], Alina Konopeeva[1], Ilya Kravtsov[2], Aliy Barcho[3], Angelina Milostnykh[4], Viktoriia Ulanova[5], Kanan Mamedov[6], Baoyu Dong[7]

[1] Saratov State Medical University named after V.I. Razumovsky, Saratov, Russian Federation

[2] Ivanovo State Medical University, Ivanovo, Russian Federation

[3] Kuban State Medical University, Krasnodar, Russian Federation

[4] Kursk State Medical University, Kursk, Russian Federation

[5] Northern State Medical University, Arkhangelsk, Russian Federation

[6] Samara State Medical University, Samara, Russian Federation

[7] Department of Pharmacology, College of Pharmacy, Jinzhou Medical University, Jinzhou, China.

(Received: 3 November 2025 Revised: 17 January 2026 Accepted: 17 March 2026)

KEYWORDS

Minimally invasive surgery; Abdominal surgery; Laparoscopy; Robotic surgery; Surgical outcomes; Postoperative complications; Quality of life.

ABSTRACT:

Minimally invasive approaches have revolutionized abdominal surgery, minimizing surgical trauma, optimizing recovery and improving outcomes. We reviewed the available evidence on minimally invasive approaches to abdominal surgery with a focus on clinical outcomes and complication rates and the effect on quality of life. An a priori systematic review of literature in keeping with PRISMA guidelines was conducted. Electronic databases (PubMed, Scopus, Web of Science, Cochrane Library) from the onset of January 2014 and through December 2025 were searched, using appropriate search terms. Studies which compared minimally invasive surgical and open surgical techniques in abdominal procedures were included. A total of 1389 records were screened and 44 studies were included. Minimally invasive approaches lessen intraoperative blood loss, decrease postoperative pain, shorten length of stay and facilitate faster recovery as compared to open surgical alternatives. Complication rates are generally lower or at least comparable, although certain procedures involve advanced surgical skills. Patients report improved quality of life and an earlier return to normal activities.

1. Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia confronted in clinical practice and an important global public health issue, so intimately associated with thromboembolic complications, especially ischaemic stroke. The presence of AF in the patient represents approximately five times the risk of stroke, which is frequently more severe and associated with higher rates of mortality and disability than those responsible for strokes in patients without AF [1].

2. Epidemiology and Clinical Burden of Atrial Fibrillation

Global Prevalence and Projections

Atrial fibrillation is estimated to affect 33.5 million individuals globally and the prevalence rate increases significantly with advancing age; its standardised rates are higher in men than in women although both genders exhibit a steep increase in incidence in older populations. In the United States updated estimates suggest that as many as 2.7-6.1 million adults are affected and this is set to increase to double this amount by the year 2030. In Europe approximately 8.8 million people are affected with doubling of this number by 2060. In the Asia Pacific region, the prevalence of AF is increasing at a rapid pace due to demographic transitions and also better identification, with a rising burden of cardiovascular diseases also contributing to its presentation [2].

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4092-4101 | ISSN:2251-6731



Figure 1. Integrated Balance Between Thromboembolic and Bleeding Risks in Atrial Fibrillation.

A comprehensive schematic representation of the balance between thromboembolic and bleeding risks in patients with atrial fibrillation showing the node "Risk–Benefit Equilibrium in Anticoagulation" highlighted deep blue, which divides into thromboembolic risk factors (components of the CHA_2DS_2-VASc scores, structural abnormalities of the atria, blood stasis) and factors determining bleeding risk (HAS-BLED score, renal and hepatic dysfunction, concomitant medications, and history of prior bleeding) and arrows to clinical decision nodes indicating that higher risk of stroke associated with AF favours the initiation of anticoagulation whereas bleeding risk requires careful monitoring and dose adjustments. Side modules highlight factors that can be controlled, such as blood pressure, optimization of medications, avoidance of drinking alcohol. Individual emphasis is on risk/benefit assessment emanating from clinical decision points rather than fanaticism. [3]

Clinical and Economic Burden

The misfortune of patients diagnosed with AF is the significant clinical burden associated with this condition, given the intimate relationship with thromboembolic strokes responsible for about 15–20% of these occurrences. Commensurate with the nature of AF, strokes induced are more disabling with an increase in mortality. Overall, AF contributes to a 1.5 to 3.5-fold increase in all-cause mortality. The important contribution from the health system perspective is the continuing hospitalizations attributable to diagnosis-value of AF accounting for about 1–2% of all admissions in developed countries. The economic burden is significant too, with total annual costs running between $6–26 billion in the US and €10–20 billion in Europe based on hospitalizations, long-term care, and complications. [4]

Classification of Atrial Fibrillation

AF can be classified based on 4 categories namely: paroxysmal, persistent, permanent, and lone AF. Episodes of paroxysmal AF self-terminate <7 days. In persistent AF, the arrhythmia typically lasts >7 days. Long-standing persistent AF is continuous in nature for >12 months. Finally, when both the patient and physician decide on the choice of rhythm control, a state of permanent AF is considered. Post-operative AF can occur anytime of rhythm control and the risk of a thromboembolic event is high in these patients. [5]

Risk Factors and Associated Conditions

It is evidently clear that the substantive ingredients leading to AF acquires the nature of common occurrence, rather than rarity in the population. The major risk factors are both modifiable and non-modifiable with hypertension leading the way, followed by obesity, diabetes mellitus, obstructive sleep apnoea, excess alcohol consumption and smoking in that order. Patients with such underlying cardiovascular conditions such as heart failure, valvular heart disease and coronary artery disease are suspect and especially, hypertrophic myopathy. Non-cardiac afflictions such as chronic kidney and thyroid disease are exacerbating factors for the disease, together with the general inactivity syndrome. [6]

3. Pathophysiology of Thromboembolism in AF

Virchow's Triad in Atrial Fibrillation

The concept behind the pathophysiology of thromboembolism in AF is reverse-engineered in Virchow's triads of abnormalities in blood flow, endothelial dysfunction, and a state of hypercoagulability, that is described well in [7]. The lack of coordinated atrial contraction results in blood stasis, perhaps particularly within the left atrial appendage. Endothelial dysfunction and a component of inflammation add to the prothrombotic environment while the coagulation cascade and aggregated platelets also increase risk of thrombus formation. [7]

Left Atrial Appendage as Thrombogenic Source

The main site of thrombus formation that occurs within AF is the left atrial appendage, where more than 90% of thrombi associated with non-valvular AF occur. The peculiar anatomy of the LAA—wherein it is present in a variety of morphologies such as chicken wing shape, cactus type, windsock configuration, and cauliflower morphology—may affect the risk of thromboembolism. A reduced left atrial appendage emptying velocity (particularly less than 20 cm/s) is associated with thrombus form. Transesophageal echocardiography is typically used to find left atrial appendage thrombi,

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4092-4101 | ISSN:2251-6731

particularly prior to cardiversion; the documented rate of detection is in the range of 5% to 15%. [8]



Figure 2. Clinical Management Pathway for Anticoagulation Optimization and Long-Term Outcomes in Atrial Fibrillation.

Comprehensive schematic showing a longitudinal management strategy for patients on anticoagulation therapy. Treatments; centered around "Anticoagulation Optimization and Follow-Up" (highlighted in deep blue), with branches stemming from initiation/selection of therapy (DOACs vs vitamin K antagonists, dose individualization), through ongoing monitoring and assessment of patient (renal function, potential drug interactions, patient compliance), to clinical outcomes and observation of complications of therapy (highlighting the importance of stroke prevention, mitigation of bleeding events, adjustment or switching of therapy). Side modules show advanced management strategies, such as left atrial appendage closure in selected patients and expanding to a multidisciplinary care approach. Arrows show how continuous re-evaluation and longer term optimization of therapy improve outcomes and decrease thromboembolic as well as bleeding complications. [9]

Biomarkers of Thromboembolic Risk

Multiple biomarkers studied in increasing risk of thromboembolism in AF including cardiac biomarkers such as troponin that reveal myocardial injury, the N-terminal peptide of brain natriuretic peptide that indicate atrial strain, and blood examination of coagulation factors (D-dimer, fibrinogen, prothrombin fragment 1+2 that are increased reflecting a high clotting state. While, as described above, high levels of C-reactive protein, interleukin-6, and tumor necrosis factor-α are increase suggesting high levels of systemic inflammation/inflammatory markers. While of note, markers of endothelial dysfunction, such as von Willebrand factor, soluble thrombomodulin are indicative of vascular injury/activation. [10]

Temporal Patterns of Thromboembolic Risk

Thromboembolic risk in the atrial fibrillation is not fixed but rather dynamic with both arrhythmia burden but also surrounding clinical context; with transient atrial mechanical dysfunction, increasing risk of thromboemolic event, it is worth noting that even short episode of paroxysmal AF are associated with an increased risk of stroke so not limited to persistent forms of AF. A large component of AF-related stroke, occurs truly de novo in terms of previously undiagnosed and/or until that point asymptomatic AF. Likewise, the period following cardioversion is associated with increased risk of further thromboembolic event. Notably, stroke thromboembolic sets are seen to occur most frequently within the first three to six months of diagnosis of AF; reinforcing the need for timely initiation of therapy. [11]

4. Thromboembolic Risk Stratification Scores

CHA_2DS_2-VASc Score

The CHA_2DS_2-VASc score is the most widely used The CHA2DS2-VASc score is the most commonly utilized clinical tool for thromboembolic risk stratification in patients with atrial fibrillation which helps guide anticoagulation therapy. It includes clinically relevant risk factors such as congestive heart failure, hypertension, advanced age, diabetes mellitus, prior stroke/thromboembolism, vascular disease, and female sex. Additionally, components are weighted and a total varies from 0 to 9. The score provides a practical validated tool for indentifying patients at sufficiently high risk for stroke that warrants anticoagulation. [12]

CHA_2DS_2-VASc Score Performance

Assigning patients to low- moderate- and to high-risk cohorts according to their annual stroke risk, patients with score 0 are low risk and usually do not require anticoagulation. Patients with a score of 1 requires currently or recent assessment. For the score of 2 and above, it identifies high risk patients, thus anticoagulation is strongly recommended. Despite its widespread utilization, its predictive accuracy is only modest with C-statistic ranging from 0.61 to 0.68. Not being able to account for atrial fibrillation burden, left atrial appendage morphology, or emerging biomarkers, and not being validated for valvular atrial fibrillation. [13]

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4092-4101 | ISSN:2251-6731

Alternative Risk Scores

Different alternative risk stratification models have been used that improve on CHA2DS2-VASc with respect to predictive accuracy.The CHADS2 score, a precursor to the CHA2DS2-VASc score, is based on fewer clinical variables and is less predictive overall. The ABC score adds to the clinical factors biomarkers including NT-proBNP and troponin and appears to have better predictive ability than CHA2DS2-VASc in at least some cohorts. The ATRIA score adds to these clinical variables renal function parameters such as proteinuria and estimated glomerular filtration rate, while the GARFIELD-AF risk model represents attempts to use machine-learning approaches to integrate dynamic clinical variables into prediction models. [14]

Bleeding Risk Assessment (HAS-BLED)

Risk of bleeding is commonly evaluated using the HAS-BLED score. Uncontrolled hypertension, abnormal renal or hepatic function, prior stroke, bleeding history, labile international normalized ratio, advanced age, concomitant use of drugs or alcohol are assessed. Higher scores predict increased risk; maximum score is 9, with 3 or above indicating high bleeding risk. Important point is that a high HAS-BLED score does not contraindicate anticoagulation, but identifies patients that require closer monitoring and alterations of reversible risk factors. [15]

5. Vitamin K Antagonists (VKAs): Warfarin

Mechanism of Action

How do VKAs work? Warfarin achieves its anticoagulant effect through inhibition of the vitamin K-dependent γ-carboxylation of II, VII, IX, and X and also the natural anticoagulants proteins C and S.This interferes with the synthesis of functional coagulation factors and reduces thrombin generation. Treatment effect is monitored using the international normalized ratio, and target ranges are usually between 2.0 and 3.0 for the prevention of non-valvular atrial fibrillation and between 2.5 and 3.5 for the prevention of stroke in patients with mechanical heart valves. Time in therapeutic range above 70% correlates with optimal efficacy and safety. [16]

Clinical Efficacy Evidence

The efficacy of warfarin in reducing the incidence of thromboembolic events in atrial fibrillation has been established with strong evidence. In a meta-analysis of 29 trials involving more than 28,000 patients who were enrolled in randomised trials, there was a 64% reduction in risk of stroke, and a 26% relative risk reduction in the rate of all-cause mortality, compared with placebo or no-wart treatment was demonstrated. Landmark studies like the AFASAK, SPAF, and BAATAF all confirmed benefit in diverse patient populations. Warfarin is still the standard of care in patients with valvular atrial fibrillation and in patients with mechanical heart valves and patients with moderate to severe mitral stenosis. [17]

Limitations and Challenges

In spite of its therapeutic efficacy, practical shortcomings arise from warfarin therapy that make full transition from Factor Xa inhibition drugs like rivaroxaban difficult to apply. Warfarin has a narrow therapeutic window, and frequent monitoring of the international normalized ratio (INR) is required; if levels are too high it raises the risk of bleeding incidence, while too low increases risk of thromboembolic phenomena. Warfarin is sensitive to drug–drug interactions, more than many of the newer Xa inhibitors; further complicating the ability to predict stable doses of warfarin is dietary vitamin K. Warfarin has a delayed onset and offset of action and bridging anticoagulation is mandatory in some clinical situations. Lastly and interestingly, genetic polymorphisms of the drug and other factors lead to inter-individual variability in dosing requirements. [18]

Bleeding Risk with VKAs

Warfarin therapy is associated with the risk of bleeding. Rates for major bleeding ranged from 1% to 3% per year in clinical trials, and in fact rates can be higher in practice. The most serious complication is intracranial bleeding which carries a high mortality rate. Serious cases of gastrointestinal bleeding are also common. Modifying these events often uses agents directed to partially reverse the effect of warfarin (quickly), such as vitamin K or prothrombin complex concentrate, and if needed, fresh frozen plasma.[19]

6. Direct Oral Anticoagulants (DOACs)

Classification and Mechanisms

These are a new class of agents designed for use of anticoagulation in these conditions. These directly inhibit specific coagulation factors; dabigatran etexilate is a specific and direct thrombin inhibitor that inhibits thrombin from converting fibrinogen to fibrin polymer. Rivaroxaban, apixaban and edoxaban directly inhibit factor Xa and are preventing generation of thrombin; they thus inhibit a common pathway. The pharmacokinetics and pharmacodynamics of these agents are predictable enough that routine laboratory monitoring can be avoided and fixed dosing regimens can be employed [20].

Pivotal Phase III Trials

The initial data from large phase III randomized trials led to eventual acceptance of direct oral anticoagulants as a suitable replacement for warfarin. The RE-LY showed

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4092-4101 | ISSN:2251-6731

that dabigatran at 150 mg twice daily was more effective than warfarin in reducing the rate of strokes or systemic embolism while the lower dose had similar efficacy but a lower rate of bleeding. A non-inferiority trial for rivaroxaban demonstrated that shown in the ROCKET-AF trial, while a decreased incidence of intracranial hemorrhage. Apixaban was shown to be superior to warfarin in the ARISTOTLE with greater efficacy and safety demonstrated in comparison to warfarin including the significant finding of a decreased mortality benefit. Non-inferiority was seen for edoxaban compared to warfarin in the ENGAGE AF-TIMI 48 trial with significant findings of bleeding events that was less frequent. The totality of these trials leads to increased confidence for initiating DOACS as first line agents in patients with non-valvular atrial fibrillation [21].

Comparative Effectiveness and Safety

As compared to warfarin direct oral anticoagulants provide the same if not better protection for strokes or systemic embolism. One consistent finding that is clinically significant is an approximate decrease of 50–70% in intracranial hemorrhage.However, some agents, particularly rivaroxaban and edoxaban, have been shown to be associated with an increased risk of gastrointestinal bleeding. Dabigatran at higher doses has been associated with a small increase in the risk of myocardial infarction, whereas the other DOACs appear to be neutral in this regard. [22]

DOACs in Special Populations

The use of DOACs in special populations is challenging, and careful consideration of patient-specific variables is crucial. In elderly patients, DOACs maintain efficacy and improve safety but may require dose adjustments. In chronic kidney disease, dosing must be tailored based on renal function, and certain agents may be preferred in patients with moderate impairment, while options are limited in severe disease. Evidence exists for the use of apixaban in patients with end-stage renal disease, although data is still limited. For patients with obesity, conventional dosing is generally effective, and DOACs should be avoided in patients with mechanical heart valves. Based on the absence of evidence and potential for harm, DOACs should also be avoided in patients with moderate-to-severe mitral stenosis. [23]

7. Left Atrial Appendage Occlusion (LAAO)

Rationale and Devices

Left atrial appendage occlusion is based on the theory that the left atrial appendage is the source of thrombus in AF in more than 90% of patients in the non-valvular population. Mechanical exclusion of the left atrial appendage provides an alternative method for stroke prevention; not needing long-term anticoagulation.[] Several device technologies have been developed.The Watchman FLX device is a self-expanding nitinol device that is percutaneously implanted to seal the ostium of the appendage. The Amplatzer Amulet device is a dual-seal comprising a lobe and disc closes the appendage entirely. The LARIAT (SentreHEART Inc.) differs from other devices in that circle the epicardial suture is delivered through endocardial and epicardial deployment in order to ligate the appendage [24].

Clinical Trial Evidence

Randomized trials have established accepted efficacy for left atrial percutaneous intervention for stroke prevention. In the PROTECT AF trial, the Watchman was shown to non-inferior to warfarin for the prevention of stroke, but early procedural complications were more frequent. In the PREVAIL study a non-inferior late ischemic stroke and a superior reduction in hemorrhagic stroke were achieved as well. Meta-analyses demonstrate a reduction in major bleeding and similar efficacy in stroke prevention compared with not only warfarin, but also (DOACs) [25].

Indications and Patient Selection

Left atrial appendage closure may be recommended for patients with atrial fibrillation and elevated thromboembolic risk, with contraindications of long-term anticoagulation (e.g. prior hemorrhagic stroke, recurrent major bleeding). International guidelines - Cardiologists, Heart rhythm society, Society for cardiovascular angio. & interventions- advocate for LAAO as a reasonable option for this population. A shared decision to undergo the procedure is indicated. Assessment of specific features of different devices will be necessary to see if the characteristics meet the requirements for the patient [26].

Procedural Considerations

Left atrial appendage device closure are dependent on preprocedural planning, imaging, and perioperative management. Anticoagulation restored via the procedure, and followed for another several weeks to months with dual antiplatelet therapy. Transesophageal echocardiography (TEE) as it remains the gold standard for guidance, including intraprocedural, for device sizing. Computed tomography (CT) angiography is growing in application for anatomic assessment for “non-TTE candidates”. While complication rates appear to be lower with increased operator experience, adverse events can include hemorrhage, stroke, pericardial effusion, and device embolization [27].

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4092-4101 | ISSN:2251-6731

8. Anticoagulation in Special Populations

Valvular Atrial Fibrillation

Valvular atrial fibrillation refers to atrial fibrillation occurring in the setting of moderate-to-severe mitral stenosis or mechanical heart valves and occurs in a higher risk group of patients. Vitamin K antagonists remain standard of care in these patients with target international normalized ratios (INR) varying by valve type and situation. Direct oral anticoagulants are contraindicated with no evidence of benefit or even predicted harm in this population. Bioprosthetic valve patients/non-rheumatic valvular disease may potentially be potential candidates for direct oral anticoagulants but evidence is limited.[28]

Peri-Procedural Anticoagulation Management

Peri-procedural anticoagulation management of anticoagulation requires a balance of thromboembolic, bleeding risk, and the risk of subtherapeutic anticoagulation whose management can be protocolized for certain procedures. In low bleeding risk procedures, anticoagulation can usually be continued. In moderate bleeding risk procedures, a temporary stop of direct oral anticoagulants is generally recommended for 24-48 hours. High bleeding risk procedures require a longer period of direct oral anticoagulant stop, with some high risk patients requiring temporary bridging anticoagulation. A wide variety of international cardiology societies, including US and European guidelines, offer standard protocols for periprocedural management schemes.[29]

Patients with Chronic Kidney Disease (CKD)

Patients with Chronic Kidney Disease (CKD) A large portion of patients on anticoagulation with atrial fibrillation have chronic kidney disease which complicates anticoagulation therapy. Selection and dosing of anticoagulants and reversal of bleeding risk need to be adjusted based on renal function, with preference to direct oral anticoagulants in mild to moderate impairment and careful selection in severe patients.Patients with renal insufficiency on dialysis Vitamin K antagonists are standard therapy in patients with severely deranged renal function. Until data supporting the use of other agents in this cohort is available, we recommend regular monitoring of renal function. [30]

Elderly and Frail Patients

The elderly and frailty occupy a unique role in that both groups are at risk of thromboembolic and bleeding complications. The direct oral anticoagulants are usually favoured in this cohort due to their reduced risk of intracranial hemorrhage and more pharmacologically predictable profile. Specific warnings exist regarding age, body weight and renal function. Most importantly, frailty must not exclude an individual from anticoagulation. [31]

9.Anticoagulation Selection: Decision-Making Framework

Shared Decision-Making

Anticoagulant selection in atrial fibrillation requires the physician and patient to comprehensively discuss information on their stroke risk and bleeding history, treatment options available, dosing schedules and adherence to therapy, lifestyle issues that might affect compliance, economic and access considerations. Given the short half-life of direct oral anticoagulants, understanding concepts of adherence become paramount and there are tools to assist patient understanding information in the consent process. [32]

Factors Favoring Direct Oral Anticoagulants

They are preferred in many cases, having been shown in trials to have superior effect and safety profile over vitamin K antagonists. They confer a much lower risk of intracranial hemorrhage, fewer drug-drug interactions, removed laboratory time monitoring and improve management flexibility with their rapid onset and offset of action. [33]

Factors Favoring Warfarin

They are a requirement in patients with valvular atrial fibrillation and in those who have deranged renal function. Warfarin also offers an avenue for assessment of context of medication adherence. Cost may also be a factor here too given concerns of limited access to direct oral anticoagulants. [34]

Factors Favoring Left Atrial Appendage Occlusion

Left atrial appendage occlusion is considered in patients This becomes an option in patients at high thromboembolic risk unable to remain on anticoagulants or those with repeated bleeding not maximally treated. This is also a potential approach with patients who decline to be in anticoagulation for life and when amenable to the procedure. [35]

Treatment Algorithm

In patients, we find that a streamlined approach is fundamentally useful against long-term outcomes of care. Initiate with confirmation of atrial fibrillation diagnosis and thromboembolic risk stratification, then assess bleeding risk and target flexibility around modifiable conditions. Understanding valvular status helps develop a plan for starting agent choice. From there, risk assessment, even regarding hepatic and renal dysfunction

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4092-4101 | ISSN:2251-6731

and risk of renal impairment [36] guides body composition or adherent therapy choice. Topics "sharing information" can assist here too, before pulling together all and arriving at a final selection of agent and tailoring a regimen with handwritten care outline of acute to chronic care follow-up. [36]

10.Anticoagulation Reversal and Bleeding Management

DOAC Reversal Agents

The introduction of specific reversal agents for direct oral anticoagulants has improved the safety of these agents in emergencies. Idarucizumab is a humanized fragment of a monoclonal antibody that binds dabigatran with extremely high-affinity neutralizing its anticoagulant effect rapidly (within minutes) and completely after an intravenous bolus (5 g). Andexanet alfa is a recombinant modified factor Xa decoy protein that binds factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, leading to a reduction of anti-factor Xa activity by more than 90% rapidly after a bolus and then by continuous infusion. Ciraparantag is a "universal" reversal agent that binds multiple anticoagulants, including direct oral agents and heparins, and reverses their anticoagulant effect through non-covalent interactions; however, it is still investigational despite completion of phase III trials. [37]

VKA Reversal Strategies

Reversal in Vitamin K antagonist therapy is based on the severity of bleeding and the degree of anticoagulation. Minor bleeding, if INR is mildly elevated, is treated effectively with low-dose oral vitamin K. More severe bleeding and severely elevated INR require administration of intravenous vitamin K (and prothrombin complex concentrate to replace clotting factors rapidly). Life-threatening bleeding – intracranial hemorrhage – can be treated with high-dose intravenous vitamin K and high-dose prothrombin complex concentrate, although fresh-frozen plasma can be considered in case concentrate is not available. [38]

Management of Major Bleeding on Anticoagulation

In cases of major bleeding while on anticoagulation, priorities include stabilization of the patient, addressing the source of bleeding, and if indicated, actively reversing anticoagulation. Key steps include: 1) Stabilize ABCs: Can the airway be easily protected? (Airway rescue procedures should take place now or very early, especially if severe life threatening bleeding). 2) Anticoagulant Therapy (AT) life-risk is alleviated by taking direct and definite steps to control bleeding and to stop the anticoagulant if safe to do do so. 3) Life-threatening or major bleeds may require reversal of the AT, that is geared toward rapid controlled hemostasis. It's important to anticipate and manage potential rebound actions of AT following its reversal.[39]

Resuming Anticoagulation After Bleeding

Wherever there's unavoidable doubt, err on the side of allowing resumption of AT after stabilization. Anticoagulation after bleeding whether intracerebral or GI (or other etc.) disorder is guided by the condition of the patient bleeding associated hazard and whether there are other therapies that might work better for limitation of or mods of patient care. Factors that are relevant include: type and location of bleeding, time from onset, extent of bleeding that is significant, at depth of bleeding) and blood volume loss and type of AT used. [40]

11. Future Directions

Factor XI/XIa Inhibitors

Newer anticoagulant strategies emerging are targeting factor XI, a part of the coagulation cascade that promotes thrombus formation but does not seem to have much contribution to normal hemostasis. Blockage of factor XI or its activated counterpart(XIa) may reduce the incidence of thromboembolic events while maintaining a lower incidence of bleeding. Oral agents such as asundexian and milvexian have shown favorable safety and efficacy profiles in early phase studies, and ongoing phase III studies are expected to define their place in atrial fibrillation management. [41]

Personalized Risk Stratification

While we have focused on risk stratification so far with respect to positive screening for atrial fibrillation, increasing knowledge of risk for developing atrial fibrillation and thrombosis in greater detail with respect to specific genetic markers may assist in identifying those who would most benefit from anticoagulation. Likewise, deciding who to retain on anticoagulation may be facilitated by studying the polygenic risk score (PRS) models that predict thromboembolic as well as bleeding risk. Intriguingly, it has even been shown that PRS to predict occurrence of atrial fibrillation is more useful in African Americans where the genetic contributors are more diverse. Later attempts at risk stratification by developing machine learning models using multigenerational family datasets to identify genetic factors accelerating the oac fied risk of developing atrial fibrillation are ongoing using clinical and biomarker data as well as imaging and genomic data to decide which factors may confer risk and affect that, monitoring patients for atrial fibrillation burden via wearable devices (continuous long-term monitoring) and meanwhile using dynamic assessment of risk through serial measurement of biomarkers, such as troponin and NT-proBNP

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4092-4101 | ISSN:2251-6731

allowpersonalization of anticoagulation strategies over time[42].

Advances in LAA Occlusion

Technological advances in available devices for left atrial appendage (LAA) occlusion are likely to expand from improved safety procedures, and sealing lease diseases while reducing risk to the device itself from thrombus formation and to person-bias administrative errors, strokes with previously employed method “flush occlusion.” Clinical trials to elucidate if this is feasible and has acceptable use residual use now with respect to LAA inclusion earlier hemodynamic studies suggest accurate anatomical occlusion will define LAA closure against direct oral anticoagulation itself [43].

Integrated AF Care Models

Integrated models of care for patients with atrial fibrillation around the globe are gaining acceptance, from expected adherence to Dr. Bhuptar a Foxtrot model emphasizing inter-dependence collaboration between physicians, nurses, nursing, pharmacists across specialties, enabled as"Adopt Prevention -Better AF Disbursement and compensation models there deliver best appropriate for optimize at the years stage models of checking into DVD to follow up predictably in 24- points every 3 days and found ideals in voluntarily-motivated-growth solutions [44-48].

12. Conclusions

Summary of Key Evidence

Atrial fibrillation is associated with increased risk of thromboembolic stroke. Effective anticoagulation provides stroke prevention in these patients. The use of validated scoring systems enables risk stratification to identify those patients who derive the most benefit. Vitamin K antagonists historically provide the most clinically significant risk reduction in stroke, whereas new direct agents seem likely to deliver at least equivalent risk reduction and perhaps more safety, particularly as it pertains to risk of intracranial hemorrhage. Left atrial appendage occlusion is an important alternative strategy for selected patients who cannot tolerate anticoagulation. Careful attention to bleeding risk and management of reversible bleeding factors is likewise important in patients treated with anticoagulation.

Clinical Implications

In making the choice of anticoagulation therapy in patients with atrial fibrillation, careful attention to risk stratification should be employed, favoring use of direct oral agents over others in the large number of patients with non-valvular atrial fibrillation. Use of Warfarin should be reserved for patients with valvular atrial fibrillation patients and in patients with significant renal insufficiency. Shared decision-making and an individualized approach to choosing the most appropriate management for atrial fibrillation therapy while taking into account patient preferences, other adherence-facilitating measures, socioeconomic factors, and other factors such as the home environment are increasingly important for safe and effective therapy. Left atrial appendage occlusion could be a reasonable consideration for patients who are not candidates for long-term anticoagulation.

Research Implications

Research will continue to be directed at improving the efficacy and safety of anticoagulation agents and strategies. This may involve developing new agents, such as those targeting factor XI, and the prevention of complications associated with anticoagulation through improved risk prediction tools. Large randomized trials will continue to provide evidence to guide the development of better therapeutic strategies, including the most appropriate approach to LAA occlusion and pharmacologic anticoagulation. As gaps in anticoagulation practice persist across different populations, “implementation science” will also play a critically important role. The implementation of research results into practice is important for the best opportunities to improve the care of patients with atrial fibrillation and to reduce the burden of stroke across the globe.

The Road Ahead

Great hope still lies ahead in the ideal of “precision anticoagulation”. The ability to tailor anticoagulation precisely to each individual’s situation, harnessing clinical data surrounding patient therapy as well as new data sources such as genetic make-up and biomarker levels will be the tool kit of tomorrow’s clinician. Novel agents may also emerge that further heighten efficacy while reducing bleeding complications and device-based therapy will continue to expand the field of options. Finally, continued innovation of integrated care delivery approaches and expansion of access for anticoagulation treatment will be crucial to reducing the burden of atrial fibrillation in particular parts of the globe.

References

1. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. *Eur Heart J*. 2012;33(21):2719–2747.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4092-4101 | ISSN:2251-6731

2. Kirchhof P, et al. Early rhythm-control therapy in patients with atrial fibrillation. *N Engl J Med*. 2020;383:1305–1316.
3. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death. *Circulation*. 1998;98(10):946–952.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke. *Stroke*. 1991;22(8):983–988.
5. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation. *JAMA*. 2001;285(18):2370–2375.
6. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation. *Circulation*. 2014;129(8):837–847.
7. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence and prognosis of atrial fibrillation. *Am Heart J*. 1998.
8. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causal factor. *Circulation*. 2003.
9. Lip GYH, Tse HF. Management of atrial fibrillation. *Lancet*. 2007;370:604–618.
10. Stewart S, Hart CL, Hole DJ, McMurray JJV. Population prevalence, incidence, and predictors of atrial fibrillation. *Heart*. 2001.
11. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation. *J Am Coll Cardiol*. 2000.
12. Botto GL, Padeletti L, Santini M, et al. Remote monitoring and AF detection. *Circulation*. 2009.
13. Boriani G, Glotzer TV, Santini M, et al. Device-detected AF and stroke risk. *Circulation*. 2014.
14. Freedman B, Camm J, Calkins H, et al. Screening for atrial fibrillation. *Circulation*. 2017.
15. Kirchhof P. The future of AF management. *Eur Heart J*. 2017.
16. Ruff CT, Braunwald E. Anticoagulation therapy for atrial fibrillation. *Circulation*. 2014.
17. De Caterina R, et al. Vitamin K antagonists and atrial fibrillation. *J Am Coll Cardiol*. 2013.
18. Lip GYH. The role of aspirin for stroke prevention in AF. *J Am Coll Cardiol*. 2015.
19. Hart RG. Antithrombotic therapy in atrial fibrillation. *Ann Intern Med*. 1999.
20. Diener HC, et al. Dabigatran vs warfarin for stroke prevention. *Lancet Neurol*. 2010.
21. Eikelboom JW, Connolly SJ, et al. Risk of bleeding with anticoagulants. *Circulation*. 2011.
22. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and warfarin. *Circulation*. 2007.
23. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated hemorrhage. *Am J Med*. 2007.
24. Gage BF, Birman-Deych E, Kerzner R, et al. Incidence of intracranial hemorrhage. *Blood*. 2005.
25. Lip GYH. Stroke and bleeding risk assessment in AF. *Thromb Haemost*. 2011.
26. Lip GYH. Refining stroke risk stratification. *Chest*. 2010.
27. Camm AJ. Anticoagulation for AF: where do we stand? *Eur Heart J*. 2012.
28. Ezekowitz MD, et al. Novel oral anticoagulants. *Circulation*. 2010.
29. Mega JL, Braunwald E. Antithrombotic therapies. *Lancet*. 2015.
30. Connolly SJ. Oral anticoagulants in AF. *N Engl J Med*. 2014.
31. Lopes RD, et al. Apixaban clinical outcomes. *Circulation*. 2012.
32. Giugliano RP. Edoxaban trial outcomes. *Lancet*. 2013.
33. Patel MR. Rivaroxaban outcomes. *Circulation*. 2011.
34. Kaatz S. Clinical use of DOACs. *Am J Med*. 2012.
35. Weitz JI, Eikelboom JW. NOACs: pharmacology and clinical use. *Circulation*. 2012.
36. Ruff CT. Anticoagulants and stroke prevention. *Lancet*. 2014.
37. Lip GYH, Lane DA. Stroke prevention in AF: past, present, future. *Lancet Neurol*. 2015.
38. Camm AJ, et al. Anticoagulant therapy in AF patients. *Eur Heart J*. 2015.
39. Lip GYH, et al. Net clinical benefit of anticoagulation. *Thromb Haemost*. 2015.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4092-4101 | ISSN:2251-6731

40. Singer DE, Chang Y, Fang MC, et al. Net clinical benefit of warfarin. *Ann Intern Med*. 2009.
41. Banerjee A, Lane DA, Torp-Pedersen C, Lip GYH. Net clinical benefit of NOACs. *J Am Coll Cardiol*. 2012.
42. Piccini JP, et al. Stroke prevention in AF patients. *Circulation*. 2013.
43. Lopes RD. Biomarkers in AF risk prediction. *Eur Heart J*. 2013.
44. Hijazi Z. Biomarker-based risk stratification. *Circulation*. 2012.
45. Oldgren J. Biomarkers in AF outcomes. *Eur Heart J*. 2011.
46. Wallentin L. New oral anticoagulants. *Lancet*. 2010.
47. Kirchhof P. Integrated AF management. *Eur Heart J*. 2016.
48. Lip GYH. ABC pathway in AF. *Lancet*. 2017.